Peptika.
Cat. 01
Type I · Lyophilised
PK-2026-BPC-15
Peptika BPC-157 vial
Lot-tracedEU pharmacyCold-chain 2–8 °C
N° 01 · Healing & Recovery

BPC-157.

Synthetic pentadecapeptide derived from human gastric juice — broad tissue-repair signalling.

Select strengthPer-vial price
Quantity
1
Total
€60.00· 1 vial
Combination presets

Pre-compounded multi-peptide vials. An EU-licensed physician reviews the blend and dosing — anything they decline is refunded.

Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.

  • ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
  • ✓Patient-named prescription only — dispensed against a valid Rx.
  • ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
  • ✓Cold-chain shipping across EU/EEA — 2–5 working days.
Overview

About BPC-157.

BPC-157 ('Body Protection Compound') is a 15-amino-acid synthetic peptide derived from a fragment of human gastric juice protein. It is one of the most extensively studied peptides in preclinical tissue-repair literature.

Animal studies consistently show acceleration of tendon, ligament, muscle, gut and vascular healing across many injury models. Human clinical trials are limited but accumulating; magistral use is supported primarily by preclinical evidence and substantial clinical experience.

Mechanism of action

BPC-157 appears to act through several converging pathways: upregulation of VEGFR2 and growth-factor receptors (driving angiogenesis), modulation of the nitric-oxide pathway (improving microcirculation), and direct stabilisation of focal adhesions during cell migration in injured tissue.

Posology · for information only

Subcutaneous injection, 250–500 mcg, 1–2 times per day. Cycles typically 4–8 weeks per injury. Local injection close to the injury site is preferred when anatomically appropriate.

Your physician sets the prescription. This is descriptive information, not a self-administration guide.

Storage

Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.

Evidence basePreclinical evidence
Indications studied
Tendon healingLigament repairGI lining supportSoft-tissue recovery
Selected references
  1. 01Sikiric P, et al. — BPC-157 — broad spectrum of healing actions. Curr Pharm Des · 2010 · doi: 10.2174/138161210791164162
Identification & specifications
INN / Name
BPC-157
Form
Lyophilised vial · subcutaneous injection
Strength
5mg vial
Manufacturing
EU-GMP Annex 1 · Grade A/B
Endotoxins
European Pharmacopoeia 2.6.14 · LAL assay
Identity & purity
HPLC + MS · > 98%
Cold chain
Validated 2–8 °C, monitored end-to-end
Regulatory basis
Directive 2001/83/EC · Article 5(1)
Logistics

2–5 working days

EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.

Legal status

Magistral preparation

Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.

Cross-border

EU prescription recognition

Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.

Same therapeutic axis

Within Healing & Recovery.

All Healing & Recovery preparations
Pre-compounded

Combinations with BPC-157.